Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) Income from Continuing Operations (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed Income from Continuing Operations for 6 consecutive years, with 544734.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 9.06% year-over-year to 544734.0, compared with a TTM value of 3310700.0 through Sep 2025, up 24.08%, and an annual FY2024 reading of 4204428.0, up 6.89% over the prior year.
  • Income from Continuing Operations was 544734.0 for Q3 2025 at Xenetic Biosciences, up from 724412.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 499473.0 in Q3 2024 and bottomed at 1337396.0 in Q2 2024.
  • Average Income from Continuing Operations over 3 years is 993790.73, with a median of 1099145.0 recorded in 2024.
  • Peak annual rise in Income from Continuing Operations hit 56.44% in 2024, while the deepest fall reached 38.6% in 2024.
  • Year by year, Income from Continuing Operations stood at 1255667.0 in 2023, then increased by 12.47% to 1099145.0 in 2024, then soared by 50.44% to 544734.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for XBIO at 544734.0 in Q3 2025, 724412.0 in Q2 2025, and 942409.0 in Q1 2025.